Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits
Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement